Barron's: 3 Cheap Biotechs With Powerhouse Potential

Barron's: 3 Cheap Biotechs With Powerhouse Potential


Biotech shares have fallen upon hard times amid a rising furor over high drug prices and slowing sales of older blockbusters. "After a rip-roaring six-year bull run, the Nasdaq Biotechnology Index has tumbled more than 27% since its July 2015 peak A string of lackluster drug launches has also hurt confidence in an industry built on the promise of innovation and breakthrough discoveries," Barron's reported.



from Biotech News